quantisnow
FeedTopReportsPricing
⌘K
Live feed
18:54:11·50d
INSIDERFiling
Vanda Pharmaceuticals Inc. logo

SVP & General Counsel Williams Timothy sold $350,755 worth of shares (42,434 units at $8.27), decreasing direct ownership by 10% to 377,450 units (SEC Form 4)

VNDA· Vanda Pharmaceuticals Inc.
Health Care
Original source

Companies

  • VNDA
    Vanda Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 5UpdateTruist$18.00
  • Nov 5UpdateB. Riley Securities$11.00
  • Oct 31UpdateH.C. Wainwright$18.00
  • Jul 11UpdateCantor Fitzgerald$11.00
  • Feb 25UpdateJefferies$12.00

Related

  • SEC9h
    SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc.
  • SEC9h
    SEC Form DEF 14A filed by Vanda Pharmaceuticals Inc.
  • SEC1d
    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
  • PR1d
    Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
  • INSIDER10d
    SEC Form 3 filed by new insider Polymeropoulos Christos Vasilios Mihael
  • INSIDER10d
    SEC Form 3 filed by new insider Howell Scott Laverne
  • PR14d
    Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
  • PR15d
    Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022